1
|
Amaya C, Luo S, Baigorri J, Baucells R, Smith ER, Xu XX. Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells. BMC Cancer 2021; 21:981. [PMID: 34470602 PMCID: PMC8408969 DOI: 10.1186/s12885-021-08722-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 08/24/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Paclitaxel (Taxol) is a microtubule-stabilizing drug used to treat several solid tumors, including ovarian, breast, non-small cell lung, and pancreatic cancers. The current treatment of ovarian cancer is chemotherapy using paclitaxel in combination with carboplatin as a frontline agent, and paclitaxel is also used in salvage treatment as a second line drug with a dose intensive regimen following recurrence. More recently, a dose dense approach for paclitaxel has been used to treat metastatic breast cancer with success. Paclitaxel binds to beta tubulin with high affinity and stabilizes microtubule bundles. As a consequence of targeting microtubules, paclitaxel kills cancer cells through inhibition of mitosis, causing mitotic catastrophes, and by additional, not yet well defined non-mitotic mechanism(s). RESULTS In exploring methods to modulate activity of paclitaxel in causing cancer cell death, we unexpectedly found that a brief exposure of paclitaxel-treated cells in culture to low intensity ultrasound waves prevented the paclitaxel-induced cytotoxicity and death of the cancer cells. The treatment with ultrasound shock waves was found to transiently disrupt the microtubule cytoskeleton and to eliminate paclitaxel-induced rigid microtubule bundles. When cellular microtubules were labelled with a fluorescent paclitaxel analog, exposure to ultrasound waves led to the disassembly of the labeled microtubules and localization of the signals to perinuclear compartments, which were determined to be lysosomes. CONCLUSIONS We suggest that ultrasound disrupts the paclitaxel-induced rigid microtubule cytoskeleton, generating paclitaxel bound fragments that undergo degradation. A new microtubule network forms from tubulins that are not bound by paclitaxel. Hence, ultrasound shock waves are able to abolish paclitaxel impact on microtubules. Thus, our results demonstrate that a brief exposure to low intensity ultrasound can reduce and/or eliminate cytotoxicity associated with paclitaxel treatment of cancer cells in cultures.
Collapse
Affiliation(s)
- Celina Amaya
- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Building, Room 415 [M877], 1550 NW 10th Avenue, Miami, FL, 33136, USA
| | - Shihua Luo
- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Building, Room 415 [M877], 1550 NW 10th Avenue, Miami, FL, 33136, USA
| | - Julio Baigorri
- HHMI High School Scholars Program, Department of Undergraduate Research and Community Outreach, University of Miami, Miami, FL, 33146, USA
| | - Rogelio Baucells
- HHMI High School Scholars Program, Department of Undergraduate Research and Community Outreach, University of Miami, Miami, FL, 33146, USA
| | - Elizabeth R Smith
- Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL, 33136, USA
| | - Xiang-Xi Xu
- Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Papanicolaou Building, Room 415 [M877], 1550 NW 10th Avenue, Miami, FL, 33136, USA.
| |
Collapse
|
2
|
Wang HY, Hou L, Li HL, Wang X, Cao Y, Zhang BY, Wang JT, Wei SJ, Dang HW, Ran HT. A nanosystem loaded with perfluorohexane and rose bengal coupled upconversion nanoparticles for multimodal imaging and synergetic chemo-photodynamic therapy of cancer. Biomater Sci 2021; 8:2488-2506. [PMID: 32211626 DOI: 10.1039/c9bm02081k] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Theranostics is a new trend integrating diagnostic and therapeutic functions in tumour research. Theranostic nanoparticles enabling both tumour imaging and drug delivery are a promising platform for image-guided cancer therapy. Photodynamic therapy (PDT) has great potential in synergy with traditional chemotherapy but faces great challenges due to hypoxia, poor targeting ability and the limited penetration depth of visible light. To solve these problems, we presented a novel nanosystem of FA/UCNPs-RB/HCPT/PFH@lipid (denoted as FURH-PFH-NPs), with a perfluorohexane (PFH) carrying rich oxygen core and a folic acid-modified lipid shell. The shell contains 10-hydroxycamptothecin (HCPT) and self-fluorescing photosensitizer compounds, namely, upconversion nanoparticles and rose bengal (UCNPs-RB). In this study, FURH-PFH-NPs aggregated in SKOV3 cells (in vitro) and the nude xenograft tumour region when combined with folic acid receptors. When triggered by low-intensity focused ultrasound (LIFU), FURH-PFH-NPs released PFH, UCNPs-RB and HCPT. The above procedure was monitored through multimodal imaging, which simultaneously guided the tumour therapy. UCNPs-RB and PFH promoted the PDT effect under LIFU. Through PDT and HCPT, we obtained better therapeutic effects and good biosafety against SKOV3 nude xenograft tumours. FURH-PFH-NPs combined with LIFU and laser irradiation might be a promising strategy for ovarian cancer.
Collapse
Affiliation(s)
- Hai-Yan Wang
- Institute of Ultrasound Imaging & Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, 400010 Chongqing, People's Republic of China. and Chongqing Key Laboratory of Ultrasound Molecular Imaging, 400010 Chongqing, People's Republic of China. and Department of Gynaecology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China
| | - Li Hou
- Department of Otolaryngology, Head and Neck Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China
| | - Hai-Liang Li
- Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China
| | - Xu Wang
- Department of Neurosurgery, 1st Hospital of Yin Chuan, 2nd Affiliated Hospital of Ningxia Medical University, Yinchuan, 750004, P.R. China
| | - Yang Cao
- Institute of Ultrasound Imaging & Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, 400010 Chongqing, People's Republic of China. and Chongqing Key Laboratory of Ultrasound Molecular Imaging, 400010 Chongqing, People's Republic of China.
| | - Bo-Yu Zhang
- School of Clinical Medicine Fujian Medical University, Fuzhou, 350000, P.R. China
| | - Jing-Tao Wang
- School of Pharmaceutical Science, Southwest University, Chongqing, 40071, P. R. China
| | - Shi-Jie Wei
- Institute of Clinical Pharmacology and Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China
| | - Hong-Wan Dang
- Institute of Clinical Pharmacology and Department of Pharmacy, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, P.R. China
| | - Hai-Tao Ran
- Institute of Ultrasound Imaging & Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, 400010 Chongqing, People's Republic of China. and Chongqing Key Laboratory of Ultrasound Molecular Imaging, 400010 Chongqing, People's Republic of China.
| |
Collapse
|
3
|
Tumor ablation using low-intensity ultrasound and sound excitable drug. J Control Release 2017; 258:67-72. [PMID: 28499816 DOI: 10.1016/j.jconrel.2017.05.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Revised: 04/11/2017] [Accepted: 05/09/2017] [Indexed: 12/23/2022]
Abstract
The cell membrane is a semi-fluid container that defines the boundary of cells, and provides an enclosed environment for vital biological processes. A sound excitable drug (SED) that is non-cytotoxic to cells is developed to disrupt the plasma membrane under gentle ultrasound insonation, 1MHz, 1W/cm2. The frequency and power density of insonation are within the physical therapy and medical imaging windows; thus the applied ultrasound is safe and not harmful to tissues. The insertion of SEDs into the plasma membrane is not toxic to cells; however, the intruding SEDs weaken the membrane's integrity. Under insonation, the ultrasound energy destabilized the SED disrupted membranes, resulting in membrane rupture and eventual cell death. In a xenograft breast tumor model, the SED alone or the ultrasound alone caused little adverse effects to tumor tissue, while the combined treatment triggered necrosis with a brief local insonation of 3min. The described sono-membrane rupture therapy could be a safe alternative to the currently used high-energy tissue ablation technology, which uses X-rays, gamma rays, electron beams, protons, or high-intensity focused ultrasound.
Collapse
|